Anavex announces u.s. fda orphan drug designation to anavex®2-73 (blarcamesine) for the treatment of fragile x syndrome

New york, nov. 07, 2022 (globe newswire) -- anavex life sciences corp. (“anavex” or the “company”) (nasdaq: avxl), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including alzheimer's disease, parkinson's disease, rett syndrome and other central nervous system (cns) disorders, today reports the u.s. food and drug administration's (fda) has granted orphan drug designation (odd) to anavex®2-73 (blarcamesine) for the treatment of fragile x syndrome.
AVXL Ratings Summary
AVXL Quant Ranking